CELG News 161.07 06/19/2014 04:34:25 Celgene Corp (CELG)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELG) 161.07 $CELG

Final Glance: Biotechnology companies
AP - Wed Jun 18, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Better Stock Today Challenge: Celgene vs. Facebook
David Williamson and Jamal Carnette, The Motley Fool - Motley Fool - Wed Jun 18, 3:32PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Celgene  takes on  Facebook  for this first...

Midday Glance: Biotechnology companies
AP - Wed Jun 18, 1:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

Early Glance: Biotechnology companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.

'Mad Money' Lightning Round: Sell, Sell, Sell Exxon Mobil
at The Street - Wed Jun 18, 5:00AM CDT
Cramer thinks Westlake Chemical is a winner but he's staying away from Smith & Wesson.

Jim Cramer's 'Mad Money' Recap: Don't Bet Against This Market
at The Street - Tue Jun 17, 7:31PM CDT
The market reacted correctly to the continued tensions in Iraq and the effect on oil, Cramer said.

How Much Does This Failure Hurt Celgene?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
Celgene 's Vidaza, which began facing U.S. generic competition in September of 2013, just can't seem to catch a break. First there was the generic competition -- which dropped sales by 27% year-over-year last quarter to $148 million. And more...

Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 12:40PM CDT
Celgene (CELG) presented data from a retrospective analysis of a phase III study on Pomalyst in the MM indication.

Up 32%: Time to Buy Bluebird Bio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 5:35PM CDT
Bluebird bio shareholders had a great day today, with the stock up 32% on some early stage data for LentiGlobin from its HGB-205 study examining the drug as a treatment for beta-thalassemia major. Two patients in the trial have gone off blood...

Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 5:10PM CDT
Celgene (CELG) has suffered a setback in its efforts to expand the label of Vidaza.

Agios Presents Data on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 4:21PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced new clinical data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies.

2 Surging Biotechs with Links to Celgene
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 16, 1:03PM CDT
Celgene is sharing its experience and opening its wallet to a slate of fledgling biotech companies in a bid to lock-up the next generation of game-changing therapies. Agios and bluebird bio are two of those companies and each reported news...

Better Stock Today Challenge: Energy Transfer Partners vs. Celgene
Joel South and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 12:00PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Energy Transfer Partners  takes on  Celgene...

Better Stock Today: Celgene vs. American Express
Tyler Riggs and David Williamson, The Motley Fool - Motley Fool - Sat Jun 14, 1:18PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Celgene  takes on  American Express  for...

Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind  Bluebird's approach is so compelling that ...

Retrospective Analysis of Overall Survival Adjusting for Patient Crossover in Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Presented at EHA
Business Wire - Sat Jun 14, 11:30AM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that a retrospective analysis of MM-003, the Company's phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination, were presented at the 19th European Hematology Association annual congress. Pomalidomide is marketed as POMALYST(R) in the United States and IMNOVID(R) in the European Union.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 133

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 91

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 68

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 110

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading

Top 5 Most Recently Viewed Articles

Epic Yoga Event by Real Essentials to Support Ovarian Cancer

Updated Category News Views 70

Real Essentials Teams Up for Ovarian Cancer Awareness To honor Ovarian Cancer Awareness Month, Real Essentials, a brand celebrated for its affordable yet high-quality apparel, partnered with Not These Ovaries, a nonprofit organization dedicated to ovarian cancer. Together, they created a unique yoga event that aimed to raise both awareness and funds for essential ovarian...

Continue Reading
MKDWELL Tech Inc. Posts H1 2024 Financial Results Drop

Updated Category News Views 115

MKDWELL Tech Inc. Financial Overview for 2024 MKDWELL Tech Inc. (NASDAQ: MKDW), a key player in the automotive electronics industry with operations in Mainland China and Taiwan, has provided an update on its financial status for the first half of the fiscal year. The latest results show a significant decline in revenue compared to the same period in the previous year....

Continue Reading
Northwest Pipe Company Strengthens Production with New Facility

Updated Category News Views 212

Northwest Pipe Company Enhances Production Capacity Northwest Pipe Company, renowned for its expertise in water-related infrastructure, has announced a significant upgrade to its production facilities. The company has recently inaugurated a new precast concrete pipe and manhole manufacturing plant aimed at addressing the rising demand in the region. With this strategic...

Continue Reading
Allient Inc. Posts Third Quarter Gains Driven by Initiatives

Updated Category News Views 99

Allient Inc. Announces Impressive Third Quarter Results Allient Inc. (NASDAQ: ALNT), a global leader in precision and specialty Motion, Controls and Power products, has announced significant financial results for its third quarter. Despite facing challenges in key industrial and vehicle markets, the company has demonstrated resilience through its operational improvements...

Continue Reading
Fulcrum Therapeutics Investor Event to Unveil PIONEER Findings

Updated Category News Views 191

Introduction to Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a pioneering biopharmaceutical company, is dedicated to enhancing the lives of individuals grappling with genetically defined rare diseases. Their primary focus is on developing innovative small molecules that target specific diseases at their root cause. This commitment drives their latest...

Continue Reading